





PHARMACEUTICAL 2021

RVL Pharmaceuticals plc
Rank 272 of 402

R V L

The relative strengths and weaknesses of RVL Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RVL Pharmaceuticals plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 81% points. The greatest weakness of RVL Pharmaceuticals plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is 25%, being 22% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	173,154
Cost of Goods Sold	74,480
Intangible Assets	166,613
Liabilities, Current	55,784
Liabilities, Non-Current	220,961
Other Assets	31,182
Other Compr. Net Income	0
Other Expenses	67,486
Other Liabilities	348
Other Net Income	-13,850
Other Revenues	177,884
Property and Equipment	0
Research and Development	19,696
Selling, General and Administrative Expense	81,961

Output Variable	Value in 1000 USD
Assets	370,949
Liabilities	277,093
Expenses	243,623
Revenues	177,884
Stockholders Equity	93,856
Net Income	-79,589
Comprehensive Net Income	-79,589
Economic Capital Ratio	25%